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Summary
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide. However, its epidemiology in many developing countries is poorly characterised.
The objective of this analysis was to evaluate respiratory symptoms which could be COPD-
related in a large sample of individuals aged 40 years in ten countries in the Middle East and
North Africa (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey
and United Arab Emirates), together with Pakistan, using a standardised methodology. A ran-
dom sample of 457,258 telephone numbers was contacted. A screening questionnaire was
administered to each eligible participant, which included six questions relating to respiratory
symptoms. Of 65,154 eligible subjects, 62,086 agreed to participate and 61,551 provided
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usable data. The age- and gender-adjusted prevalence of symptoms (persistent productive
cough or breathlessness or both) was 14.3% [95%CI: 14.0 14.6%], ranging from 7.2% in UAE
to 19.1% in Algeria. Symptoms were more frequent (p < 0.0001) in women (16.7%) than in
men (12.2%). The adjusted prevalence of COPD according to the “epidemiological” deﬁnition
(symptoms or diagnosis and cigarette use10 pack·years) was 3.6% [95%CI: 3.5 3.7%] (range:
1.9% in UAE to 6.1% in Syria). COPD was more frequent (p < 0.0001) in men (5.2%) than
in women (1.8%). The frequency of symptoms was signiﬁcantly higher in cigarette smokers
(p < 0.001), as well as in waterpipe users (p < 0.026). In conclusion, the prevalence of COPD in
this region seems to be lower than that reported in industrialised countries. Under-reporting
and risk factors other than smoking may contribute to this difference.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is charac-
terised by chronic inﬂammation of the lung with consequent
respiratory impairment and distress.1,2 The most common
symptoms of COPD are breathlessness, excessive sputum
production, and a chronic cough.3 The Global Initiative
for Obstructive Lung Disease (GOLD) recommends that the
diagnosis of COPD should be based on clinical symptoms
of chronic bronchitis (cough and sputum production for
at least 3 months/year for at least two years) or emphysema
(breathlessness and coughing), and/or a history of exposure
to risk factors for the disease, especially cigarette
smoking, conﬁrmed by obstructed airﬂow measured with
spirometry.4,5
In 2005, the World Health Organisation (WHO) estimated
that 210 million people had COPD and three million people
died of COPD that year. Total deaths from COPD are
projected to increase in the next twenty years, making
it the third leading cause of death in the world unless
urgent action is taken to reduce underlying risk factors,
especially tobacco use and air pollution.6 In the USA, the
NHANES III survey was conducted in a sample of 16,084
adults from the general population. Fourteen percent of the
adult population fulﬁlled the GOLD criteria for a diagnosis
of COPD, which would correspond to 24 million individuals
nationwide.7
Most of the available information on the prevalence of
COPD symptoms has come from industrialised countries.
However, available epidemiological data underestimate the
total prevalence of COPD, because the disease is usually
not diagnosed until it is clinically apparent and moderately
advanced.3 For example, a Swedish study has estimated
that only 20 30% of subjects with COPD who met the GOLD
criteria had been diagnosed as having COPD.8 In the Middle
East and North Africa (MENA) region, epidemiological data
on COPD are either limited or localised to small regions and
do not necessarily represent national prevalence estimates.
Community-based prevalence surveys are rare due to the
high cost and complexity of organising them.
For these reasons, we performed an international survey
(BREATHE) in the general population of eleven countries
of the MENA region in order to describe the prevalence
of symptoms that could be COPD-related (persistent
productive cough and breathlessness) in each country.
Methods
This was a cross-sectional epidemiological survey of COPD
conducted in a random sample of the general population of
eleven countries: Algeria, Egypt, Jordan, Lebanon, Morocco,
Pakistan, Saudi Arabia, Syria, Tunisia, Turkey and UAE,
between June 2010 and December 2011. This analysis
estimates the prevalence of symptoms which could be COPD-
related in these countries. The methodology used in the
study has been described in detail in the methodology
article.9
Study sample
A general population sample of at least 10,000 subjects in
each country or zone was generated from random telephone
numbers. A structured interview was carried out with all
eligible subjects by telephone. All subjects aged 40 years
who agreed to participate in the study were eligible.
Subjects not domiciled in the country or those of foreign
origin who had been resident in the country for <6 months at
the time of the interview as well as those who had comorbid
mental illness were excluded.
Data collection
When the contact was established, the interviewer ex-
plained to the interviewee the goal of the study and the
next steps. If the subjects agreed to participate in the study,
they were invited to complete two questionnaires. The ﬁrst
“screening questionnaire” collected data on demographics,
potential respiratory symptoms and smoking habits. The
items related to respiratory symptoms were the occurrence
and frequency of productive cough or breathlessness, and
known respiratory disease (Table 1). The second, more
detailed questionnaire was administered to the screened
population with symptoms. This documented risk factors,
comorbidities, respiratory disease history, clinical symp-
toms, impact on daily life and disease management. The
present article presents the results from the screening
questionnaire; data from the second questionnaire are
presented elsewhere in this supplement.10 12
Case deﬁnition
Subjects were considered to have symptomatic COPD if they
fulﬁlled the “epidemiological” deﬁnition of COPD used in
this study, which includes two criteria. The ﬁrst criterion
was EITHER a diagnosis of COPD, emphysema or chronic
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Table 1
Items used to document respiratory symptoms in the screening questionnaire
5. Do you suffer from persistent bronchitis or coughing with phlegm or sputum from the chest for the last 2 years or
more?
Yes
No
6. How many MONTHS in the past 12 months have you had bronchitis or chronic coughing with phlegm/sputum from the
chest?
Number of months per year
7. For how many years have you had bronchitis or chronic coughing with phlegm/sputum from the chest for at least
3 months?
Years with repeated bronchitis
8. At what age did you ﬁrst develop bronchitis or coughing with phlegm or sputum?
Years old
9. Have you been repeatedly short of breath over the past 12 months?
Yes
No
10. At what age did you ﬁrst develop shortness of breath?
Years old
bronchitis OR the presence of coughing with phlegm or
sputum (productive cough), breathlessness or symptoms
consistent with chronic bronchitis. The second criterion was
a lifetime smoking exposure of 10 pack·years. The number
of pack·years of cigarette exposure is deﬁned as (number of
cigarettes smoked per day/20) × (number of years smoked).
Subjects were considered to have chronic bronchitis if they
fulﬁlled the GOLD deﬁnition, namely “the presence of cough
or sputum production for at least 3 months in each of two
consecutive years”.5 The potential relationship between the
presence of respiratory symptoms and smoking was also
assessed. Subjects with diagnosed a1-trypsin deﬁciency who
reported the above respiratory symptoms were also assigned
to the COPD group, regardless of smoking status.
Statistical analysis
Frequency rates were calculated together with their 95%
conﬁdence limits, and adjusted for age and gender unless
otherwise speciﬁed. Missing data were not replaced and the
relatively few subjects for whom data were missing were
excluded from the calculation of frequency rates.
Associations between cigarette smoking and respiratory
symptoms were quantiﬁed using odds ratios and were tested
using the c2 test. Associations between waterpipe use and
symptoms were assessed after adjustment for cigarette
smoking. Adjusted odds ratios were used to quantify the
association and the Cochran Mantel Haenszel statistic was
used to test the null hypothesis.
Results
Study sample
A total of 62,086 subjects were interviewed regarding
smoking habits. There were equal numbers of men and
women (sex ratio: 1.04; 31,673 were men). Overall, 46.4% of
subjects (n = 28,815) were aged between 40 and 49 years,
29.7% (n = 18,427) from 50 to 59 years and 23.9% (n = 14,844)
aged 60 years.
Prevalence of COPD-related respiratory symptoms
The respiratory symptoms assessed during the screening
phase were self-reported productive cough and breathless-
ness. Of the subjects enrolled in the study, 8,850 reported
at least one of these symptoms. The age- and gender-
adjusted prevalence of these respiratory symptoms was thus
14.3% [95%CI: 14.0 14.6%] of the general population of
the MENA region aged over forty years. The prevalence of
symptoms adjusted by age and gender in each participating
country is presented in Fig. 1. The lowest prevalence
was in UAE (7.2% [95%CI: 6.4 8.1%]) and the highest in
Algeria (19.1% [95%CI: 17.9 20.4%]). Breathlessness alone
was the most frequently reported symptom in all study
countries (~60% of all reports). The mean age at symptom
onset was 43.3±12.1 years for productive cough and
43.9±11.4 years for breathlessness.
COPD-related respiratory symptoms were more frequently
reported (p < 0.0001) by women (16.7% [95%CI: 16.3
17.1%]) than by men (12.2% [95%CI: 11.8 12.6%]) (Fig. 2).
This difference was particularly observed for breathlessness
alone which was reported by 10.0% of women compared to
6.8% of men (p < 0.0001).
Prevalence of chronic bronchitis
Subjects were considered to have chronic bronchitis when
the reported respiratory symptoms fulﬁlled the GOLD
deﬁnition of chronic bronchitis. A total of 1,600 subjects
in the study population fulﬁlled this deﬁnition. Accordingly,
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Figure 1. Age- and gender-adjusted prevalence of COPD-related symptoms in the general population aged over forty years in
participating countries.
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Figure 2. Age adjusted prevalence of respiratory symptoms.
the prevalence of chronic bronchitis in the general
population was 2.6% [95%CI: 2.5 2.7%] (Fig. 3). Around
one ﬁfth (18.2%; 2.6/14.3) of subjects who reported
some COPD-related respiratory symptoms and nearly half
(42.6%; 2.6/6.1) of those who reported productive cough
were considered to have chronic bronchitis. Overall, chronic
bronchitis was more frequently documented (p < 0.0002) in
women (2.8% [2.6 3.0%]) than in men (2.4% [2.2 2.5%]).
Prevalence of COPD
A total of 2,187 subjects fulﬁlled the “epidemiological”
deﬁnition of symptomatic COPD as cited above. Accordingly,
the prevalence of COPD adjusted by age and by gender in
the general population of the MENA region was 3.6% [95%CI:
3.5 3.7%] ranging from 1.9% (95%CI [1.4 2.4%]) in UAE to
6.1% [95%CI: 5.3 6.9%] in Syria (Fig. 4).
Gender-speciﬁc COPD prevalence adjusted by age in each
of the eleven countries is presented in Fig. 5. Overall, COPD
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Figure 3. Prevalence of chronic bronchitis in subjects who fulﬁl the GOLD deﬁnition.
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Figure 4. Prevalence of COPD according to the epidemiological deﬁnition in each participating country.
was more frequently documented (p < 0.0001) in men (5.2%
[95%CI: 4.9 5.4%]) than in women (1.8% [95%CI: 1.7 2.0%]).
The prevalence of COPD in men ranged from 2.6% [95%CI:
1.8 3.3%] in UAE to 9.7% [95%CI: 8.3 11.2%] in Syria. In
women the highest rate was detected in Lebanon (4.7%
[95%CI: 3.7 5.7%]).
The prevalence rate of COPD in subjects aged 40 49 years
was signiﬁcantly lower than that in the other age groups:
3.1% [95%CI: 2.9 3.3%] in subjects aged 40 49 years versus
3.9% [95%CI: 3.7 4.2%] in those aged 50 59 years and 3.8%
[95%CI: 3.5 4.1%] in those aged 60 years (p < 0.0001). The
highest prevalence rate was documented in Syrian subjects
aged 60 years (7.2% [95%CI: 5.2 9.1%]).
History of known respiratory disease
In the study population, 1,872 subjects reported a
previous respiratory diagnosis. This was most frequently
chronic bronchitis (n = 1,446; 2.4% of the study population),
COPD (n = 662; 1.1%), emphysema (n = 196; 0.3%), and
a1-antitrypsin deﬁciency (n = 107; 0.2%). The mean age at
diagnosis was 43.0±11.7 years.
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Figure 5. Gender-speciﬁc COPD distribution in the general population of the participating countries.
Table 2
Relationship between COPD symptoms and smoking
No cigarette smoking (N=42,923) <10 pack·years
(N =4,307)
10 pack·years
(N=13,284)
Productive cough
(N = 3,636)
2,204 (5.1%)
OR = 1
283 (6.6%)
OR = 1.30 [1.14 1.48]
p < 0.0001
1149 (8.6%)
OR = 1.75 [1.62 1.88]
p < 0.0001
Chronic bronchitis
(N = 1,562)
920 (2.1%)
OR = 1
92 (2.1%)
OR = 1.00 [0.80 1.24]
NS
550 (4.1%)
OR = 1.97 [1.77 2.20]
p < 0.0001
Breathlessness
(N = 6,961)
4,709 (11.0%)
OR = 1
465 (10.8%)
OR = 0.98 [0.89 1.09]
NS
1787 (13.5%)
OR = 1.26 [1.19 1.34]
p < 0.0001
No waterpipe use (N=58,451) Waterpipe use (N=2,173)
Productive cough
(N = 3,640)
3,481 (6.0%)
Adjusted ORa = 1
159 (7.3%)
Adjusted ORa = 1.29 [1.09 1.51]
p = 0.007
Chronic bronchitis
(N = 1,568)
1,496 (2.6%)
Adjusted ORa = 1
72 (3.3%)
Adjusted ORa = 1.42 [1.12 1.80]
p = 0.026
Breathlessness
(N = 6,978)
6,695 (11.5%)
Adjusted ORa = 1
283 (13.0%)
Adjusted ORa = 1.18 [1.04 1.34]
p = 0.018
NS: not signiﬁcant (p > 0.05)
a Adjusted for cigarette smoking.
Association between respiratory disease and
smoking
The relationship between the presence of COPD-related
respiratory symptoms and smoking status was assessed
and is presented in Table 2. Firstly, the association
between cumulative cigarette exposure and symptoms
was evaluated. The frequency of all three symptom
clusters evaluated (productive cough, chronic bronchitis
and breathlessness) was signiﬁcantly higher in cigarette
smokers, and in particular in those individuals who had
smoked over ten pack·years. Given that around half of
waterpipe users also smoked cigarettes, the association
between waterpipe use and symptoms was determined after
adjusting for cigarette consumption. Again, a signiﬁcant
association was observed for all three symptom clusters. For
both cigarette smoking and waterpipe use, the association
was most robust for chronic bronchitis and weakest for
breathlessness.
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Discussion
The BREATHE study is to our knowledge the ﬁrst large-
scale international study of the prevalence of symptoms
which could be COPD related (productive cough and
breathlessness) in the general population of the MENA
region aged over forty years. Our study showed that
14.3% of the general population of the eleven participating
countries reported these respiratory symptoms which could
be consistent with a diagnosis of COPD. Breathlessness
alone was the most common reported symptom with a
prevalence of 8.3%. Respiratory symptoms fulﬁlling the
GOLD deﬁnition of chronic bronchitis were reported by
1,600 subjects (2.6%).
According to the “epidemiological” deﬁnition of COPD
used in our study, COPD was reported by 2,187 subjects,
corresponding to a prevalence of 3.6%. COPD was more
frequent in men than in women (5.2% and 1.8% respectively),
and was more frequently documented in subjects aged
50 59 years and 60 years than in those aged 40 49 years
(p < 0.0001). For subjects with a diagnosed respiratory
disease, the mean age at diagnosis was 43.3±12.1 years,
which is close to the age at which respiratory symptoms were
reported to have ﬁrst appeared.
Comparison with published epidemiological data on the
prevalence of COPD symptoms is difﬁcult, as they vary con-
siderably according to the methodology and the deﬁnition
of COPD used. However, the Confronting COPD surveys in
North America and Europe used a comparable methodology
and the same COPD deﬁnition as that used in the BREATHE
study. The proportion of subjects with symptomatic COPD
in this large study was around 6.5% and was relatively
homogenous between different countries.13 The proportion
that we observed in the BREATHE study (3.6%) was around
half of this.
Several factors may contribute to this difference. Firstly,
both smoking and respiratory symptoms may be under-
reported in telephone interviews with members of the
general population. As discussed in the accompanying
article on smoking habits in the BREATHE population,
potential under-reporting of smoking is a particular issue
in women,12 since it is not always regarded as socially
acceptable for women to smoke in some participating
countries. In this respect, it is pertinent that, while
more women than men reported COPD-related symptoms
in our study, inclusion of the smoking criterion in the
epidemiological deﬁnition of COPD resulted in a threefold
lower prevalence rate in women than in men. Under-
reporting of productive cough may also occur, since some
respondents may consider that coughing, at least when it
is not severe, is a ‘normal’ behaviour in older people who
smoke. The ﬁnding that productive cough was reported less
frequently than breathlessness would be consistent with
such under-reporting.
In addition, certain groups of subjects with COPD may not
have been captured in our study. These include subjects
with chronic airway obstruction who have been exposed
to airborne risk factors other than smoking (see below),
subjects with asymptomatic airway obstruction or mild
symptoms that were not considered worthy of reporting, and
those with COPD incorrectly diagnosed as asthma.
To our knowledge, few epidemiological studies have
estimated the prevalence of chronic bronchitis using a
methodology similar to that used in our study. The principal
differences between this study and previous studies concern
age and the selected study population. For example, a
community-based study performed in the USA from 1971 to
2000 showed that the rate of self-reported lifetime chronic
bronchitis in adults aged >18 years was 5.95%.14 Another
study conducted in eight European cities in 2004 in the
same age group provided an estimate of 6.2%.15 In contrast,
the majority of epidemiologic studies on chronic bronchitis
conducted in middle-income countries have been limited
to speciﬁc population groups such as miners or hospitalised
patients.14 The prevalence of breathlessness found in the
BREATHE study was similar to that reported in a French
study performed in a large sample (n = 2,758) of individuals
>40 years of age, which estimated the prevalence of
breathlessness to be 9%.16
Our study shows that around two-thirds of subjects
reporting symptoms evocative of COPD are not current
smokers. These ﬁndings contrast with those of the
Confronting COPD study in North America and Western
Europe,13 where around half were smokers, but are similar
to those found in the literature with respect to middle-
income countries. For example, a study performed in the
general population aged 40 80 years in Abu Dhabi (UAE) in
2010, reported that 75% of subjects with COPD (according to
the GOLD deﬁnition) were non-smokers.12 In our study, it is
particularly striking that, of the 1,607 subjects who fulﬁlled
the GOLD symptom criteria for chronic bronchitis, which is
one of the clinical phenotypes of COPD, 985 (61.3%) declared
that they did not smoke cigarettes or reported a cumulative
exposure <10 pack·years. If these 985 subjects are included
for the estimation of the prevalence of COPD, the overall
prevalence rate would rise to 5.2%. Nonetheless, we
observed a clear association between cumulative cigarette
exposure and the frequency of COPD-related symptoms,
suggesting that this remains a major risk factor.
This suggests that COPD risk factors other than smoking,
such as workplace pollution and indoor air pollution from
biomass fuel may be involved.17 Many studies performed
in developing countries have shown that indoor air
pollution from biomass fuel is an important risk factor for
COPD particularly in rural non-smoking women in these
countries.17 21 Another speciﬁc risk factor in this region
may be waterpipe use, and we observed a signiﬁcant
association between waterpipe use and the frequency of
respiratory symptoms, independent of the risk associated
with concomitant cigarette smoking. In this respect, a
Lebanese survey performed in 2009 showed that waterpipe
smoking may have the same harmful effect on health
as cigarette smoking.22 The epidemiological deﬁnition of
COPD used in our study captures COPD related to cigarette
smoking. While it is well known that this is the dominant
risk factor in Western countries in COPD patients,13 it is
likely that a signiﬁcant proportion of COPD in the developing
countries and speciﬁcally in countries in the MENA region is
more related to other risk factors such as indoor air pollution
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from biomass fuel or waterpipe use. Therefore, a future
epidemiological deﬁnition of COPD should take into account
risk factors other than cigarette smoking.
The strength of our study resides in the large sample of
subjects assessed using a homogeneous methodology in all
participating countries. As COPD occurs mainly in adults
and elderly subjects, our study include only subjects aged
40 years in order to limit potential inclusion bias which
could lead to an underestimate of the COPD prevalence
in these age groups. We also systematically documented
smoking habits, since smoking represents a major risk factor
for COPD.
However, our study has some limitations. It is possible
that the prevalence of COPD was underestimated, since
COPD symptoms may not be recognised by the subjects
themselves and COPD is not necessarily diagnosed until it
is moderately advanced. In addition, the case deﬁnition for
COPD is problematic for developing countries, where the
prevalence of tuberculosis is high and may be the origin
of chronic irreversible airﬂow obstruction in a signiﬁcant
proportion of individuals.14
In conclusion, the BREATHE study showed that 3.6% of
individuals in the general population of the MENA region
fulﬁlled the epidemiological deﬁnition of COPD, lower than
that reported in industrialised countries. In addition, causes
of COPD other than cigarette smoking, such as waterpipe
use, may be relatively more important in the MENA region.
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